Results 31 to 40 of about 51,276 (310)

The role of rivaroxaban in eosinophilic myocarditis

European Heart Journal - Case Reports, 2022
Abstract This is a case of eosinophilic myocarditis which had large left-ventricular thrombus seen on echocardiography and cardiac magnetic resonance imaging which was successfully treated with a highly selective direct Factor Xa inhibitor—rivaroxaban.
Carla Bodagh, Chris Sawh, Pankaj Garg
openaire   +4 more sources

Rivaroxaban Plasma Levels and Levetiracetam

Annals of Internal Medicine, 2020
Contains fulltext : 229204.pdf (Publisher’s version ) (Open Access)
Brouwer, M.A., van Vugt, S.P.G., Jaspers Focks, J., Damen, S.A.J., Damen, S.A.J., Verheugt, F.W.A.   +5 more
openaire   +7 more sources

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects

Frontiers in Pharmacology, 2022
The present drug-drug interaction study investigates whether single or repeated doses of 240 mg Ginkgo biloba extract EGb 761® alter the pharmacokinetics or pharmacodynamics of rivaroxaban in healthy subjects.
Robert Hoerr, Andrea Zimmermann, Friedeborg Seitz, Angelika Dienel   +3 more
doaj   +1 more source

Blood loss in primary total knee arthroplasty-body temperature is not a significant risk factor-a prospective, consecutive, observational cohort study [PDF]

, 2015
BACKGROUND: Hypothermia related to anaesthesia and operating theatre environment is associated with increased blood loss in a number of surgical disciplines, including total hip arthroplasty.
Beller, Elaine, Dan, Michael, Jones, Peter, Liu, David, Martos, Sara Martinez, Randle, Ray   +5 more
core   +2 more sources

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin

Gastroenterology Research and Practice, 2016
Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods.
Muhammed Sherid, Samian Sulaiman, Salih Samo, Husein Husein, Ruth Tupper, Charles Spurr, Humberto Sifuentes, Subbaramiah Sridhar   +7 more
doaj   +1 more source

Rivaroxaban in atrial fibrillation

Vascular Health and Risk Management, 2012
Warfarin is the traditional therapeutic option available to manage thromboembolic risk in atrial fibrillation. The hemorrhagic risk with warfarin depends mainly on the international normalized ratio (INR). Data from randomized controlled trials show that patients have a therapeutic INR (2.00-3.00) only 61%-68% of the time while taking warfarin, and ...
Lucas San Miguel, Mariano Giorgi
openaire   +4 more sources

Rivaroxaban: Drug review

Cancer Research, Statistics, and Treatment, 2020
Cancer-associated thrombosis is a challenging problem when treating patients with cancer. It is recurrent and difficult to treat because of the increased risk of bleeding. Low-molecular-weight heparin is the standard of care for treating cancer-associated venous thromboembolism/pulmonary embolism (VTE/PE).
Anuj Gupta, Vanita Noronha, Arpita Singh, Amrita Singh, Deepak Singh, Parul Singh, Abhishek Singh   +6 more
openaire   +3 more sources

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

Rivaroxaban: A novel anticoagulant

Indian Journal of Medical Sciences, 2010
For more than 50 years, warfarin has single-handedly ruled the world of anti-coagulation without any competition, whatsoever! The anticoagulant was made available in 1940 and since then no other anti-coagulant has ever been able to match it in the clinical arena.
CL Nawal, Muzaffar Ali
openaire   +3 more sources

Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Analytical Cellular Pathology, 2020
Background. Pulmonary embolism (PE) is a life-threatening disease. Target-specific anticoagulant rivaroxaban is a direct factor Xa inhibitor that can be safely used without laboratory monitoring. Objective.
Yan Huang, Linli Duan, Wenjun He, Cheng Hong, Yehui Guo, Xinni Wang, Nuofu Zhang, Yanghang Chen, Tao Wang, Jian Wang, Chunli Liu   +10 more
doaj   +1 more source